Showing 2,121 - 2,140 results of 13,894 for search '(( significant increase decrease ) OR ( significant ((main decrease) OR (point decrease)) ))', query time: 0.48s Refine Results
  1. 2121
  2. 2122
  3. 2123
  4. 2124
  5. 2125
  6. 2126
  7. 2127
  8. 2128
  9. 2129

    CHAMPS pilot Hb dataset. by Jeanie du Toit (20721918)

    Published 2025
    “…Postmortem testing showed a significant decrease in hemoglobin concentrations compared to antemortem levels. …”
  10. 2130
  11. 2131

    Data Sheet 2_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf by Mi-Ae Lyu (20413646)

    Published 2025
    “…The addition of ruxolitinib increases UCB-Treg cell persistence in peripheral blood in vivo and decreases the soluble form of human inflammatory cytokines including IFN-γ, TNF-α, and sCD40L in plasma along with improvement of skin lesions in SLE xenografts. …”
  12. 2132

    Data Sheet 3_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf by Mi-Ae Lyu (20413646)

    Published 2025
    “…The addition of ruxolitinib increases UCB-Treg cell persistence in peripheral blood in vivo and decreases the soluble form of human inflammatory cytokines including IFN-γ, TNF-α, and sCD40L in plasma along with improvement of skin lesions in SLE xenografts. …”
  13. 2133

    Data Sheet 1_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf by Mi-Ae Lyu (20413646)

    Published 2025
    “…The addition of ruxolitinib increases UCB-Treg cell persistence in peripheral blood in vivo and decreases the soluble form of human inflammatory cytokines including IFN-γ, TNF-α, and sCD40L in plasma along with improvement of skin lesions in SLE xenografts. …”
  14. 2134
  15. 2135
  16. 2136
  17. 2137
  18. 2138
  19. 2139
  20. 2140